FILTER BY:
Details
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Address: 195 Little Albany St, New Brunswick, NJ 08901, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: False
- Peritoneal: False
- Pericardial: False
- Tunica Vaginalis: False
Type: N/A
Condition: Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
Description: This is a Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Research Center: Rutgers University
Treatment Interventions: DRUG: MRTX1719
Potential Impact: Fake Data
Clinical Trial Number: NCT05245500
Phase: Phase 1, Phase 2
Status: Recruiting
